Alaunos Therapeutics(Formerly ZIOPHARM Oncology)
Financials
Estimates*
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | <1m | 2.7m | <1m | - | - |
| % growth | - | - | - | 654 % | (100 %) | - | - |
| EBITDA | (51.8m) | (71.8m) | (67.5m) | (27.3m) | (23.8m) | - | - |
| % EBITDA margin | - | - | (18646 %) | (999 %) | (523652 %) | - | - |
| Profit | (107m) | (72.7m) | (71.8m) | (34.5m) | (31.9m) | (8.7m) | (34.2m) |
| % profit margin | - | - | (19849 %) | (1267 %) | (702870 %) | - | - |
| EV / revenue | - | - | 470.6x | 45.3x | 2184.2x | - | - |
| EV / EBITDA | -13.5x | -5.4x | -2.5x | -4.5x | -0.4x | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $18.1m | Series A | |
| N/A | N/A | IPO | |
$37.0m | Post IPO Equity | ||
| N/A | $5.1m | Post IPO Debt | |
| N/A | $733k | Grant | |
| N/A | $57.5m | Post IPO Equity | |
| N/A | $120m | Post IPO Equity | |
| N/A | $8.4m | Post IPO Equity | |
* | N/A | $15.7m | Post IPO Equity |
| Total Funding | $18.8m | ||
Related Content
Recent News about Alaunos Therapeutics(Formerly ZIOPHARM Oncology)
EditZiopharm Oncology is a biotechnology company focused on developing advanced gene and cell therapies to combat cancer. Operating in the immuno-oncology sector, Ziopharm serves patients with blood cancers and solid tumors. The company leverages its proprietary technologies, such as the Sleeping Beauty non-viral genetic modification platform, to create CAR T cells and TCRs that can be rapidly and cost-effectively manufactured. Ziopharm's business model revolves around the development and clinical trials of these therapies, aiming to bring them to market for widespread medical use. Revenue is generated through partnerships, licensing agreements, and eventual commercialization of their therapies. The company is currently in various phases of clinical trials, including Phase 1 trials for their Rapid Personalized Manufacturing (RPM) CAR T technology targeting relapsed CD19 leukemias and lymphomas. Ziopharm's mission is to harness the power of the immune system to provide innovative treatment options for cancer patients.
Keywords: immuno-oncology, gene therapy, cell therapy, CAR T cells, TCRs, cancer treatment, genetic modification, clinical trials, biotechnology, RPM technology.